https://www.selleckchem.com/Proteasome.html
Background. The comparative efficacy of ceftazidime/avibactam and meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown.Methods. This was a multicenter, retrospective cohort study of adults with CRE infections who received ceftazidime/avibactam or meropenem/vaborbactam for ≥72 hours from February 2015 to October 2018. Patients with a localized urinary tract infection and repeat study drug exposures after the first episode were excluded. The primary endpoint was clinical success compare
Like
Comment
Share
